PharmaShots Weekly Snapshot (June 17 – 21, 2019)

Sanofi and Regeneron Report Results of REGN3500 in P-II Study for Asthma

1.Sanofi and Regeneron Report Results of REGN3500 in P-II Study for Asthma

Published: Jun 21, 2019 | Tags: Sanofi, Regeneron, Report, Results, REGN3500, P-II, Study, Asthma

Bayer Initiates P-III Study of Aflibercept for the Prevention of Blindness in Premature Infants with Retinopathy of Prematurity

2.Bayer Initiates P-III Study of Aflibercept for the Prevention of Blindness in Premature Infants with Retinopathy of Prematurity

Published: Jun 21, 2019 | Tags: Bayer, Initiates, P-III, Study, Aflibercept, Prevention, Blindness, Premature Infants, Retinopathy of Prematurity

Valneva Terminates its Agreement with GSK for Regaining Control of Research and Development Assets

3. Valneva Terminates its Agreement with GSK for Regaining Control of Research and Development Assets

Published: Jun 20, 2019 | Tags: Valneva, Terminates, 2007, Agreement, GSK, Regain Control, Assets

IBRI Signs a License Agreement with Eli Lilly to Access its Fab Phage Display Library

4. IBRI Signs a License Agreement with Eli Lilly to Access its Fab Phage Display Library

Published: Jun 20, 2019 | Tags: IBRI, Signs, License Agreement, Eli Lilly, Access, Fab Phage Display Library

Novo Nordisk’s Esperoct (turoctocog alfa pegol, N8-GP) Receives European Commission Approval for the Treatment of Hemophilia A

5. Novo Nordisk’s Esperoct (turoctocog alfa pegol, N8-GP) Receives European Commission Approval for the Treatment of Hemophilia A

Published: Jun 20, 2019 | Tags: Novo Nordisk, Esperoct, turoctocog alfa pegol, N8-GP, Receives, European Commission, Approval, Treatment, Hemophilia A

Alexion’s Ultomiris (ravulizumab) Receives MHLW’s Marketing Authorization for Paroxysmal Nocturnal Hemoglobinuria in Adults

6.Alexion’s Ultomiris (ravulizumab) Receives MHLW’s Marketing Authorization to Treat Paroxysmal Nocturnal Hemoglobinuria in Adults

Published: Jun 18, 2019 | Tags: Alexion, Ultomiris, ravulizumab, Receives, MHLW, Marketing Authorization, Paroxysmal Nocturnal Hemoglobinuria, Adults

Resolution Bioscience Collaborates with Janssen to Develop Cell-Free DNA CDx for Niraparib to Treat Prostate Cancer

7. Resolution Bioscience Collaborates with Janssen to Develop Cell-Free DNA CDx for Niraparib to Treat Prostate Cancer

Published: Jun 19, 2019 | Tags:Resolution Bioscience, Collaborates, Janssen, Development, Cell-Free, DNA, CDx, Prostate Cancer

Alexa to Detect Cardiac Arrest with AI-Enabled Tool for Smart Speakers and Smartphones

8. Alexa to Detect Cardiac Arrest with AI-Enabled Tool for Smart Speakers and Smartphones

Published: Jun 19, 2019 | Tags: Alexa, Detect, Cardiac Arrest, AI- Enabled Tool, Smart Speakers, Smartphones

Amgen Signs a Research Agreement with University of Washington's IPD for the Development of Protein-Based Therapies

9. Amgen Signs a Research Agreement with the University of Washington’s IPD for the Development of Protein-Based Therapies

Published: Jun 19, 2019 | Tags: Amgen, Signs, Research Agreement, University of Washington, IPD, Development, Protein-Based Therapies

Gilead Signs an Agreement with Nurix to Develop and Commercialize Protein Degradation Therapies for Cancer and Other Disease

10.Gilead Signs an Agreement with Nurix to Develop and Commercialize Protein Degradation Therapies for Cancer and Other Disease

Published: Jun 19, 2019 | Tags: Gilead, Signs, Agreement, Nurix, Develop, Commercialize, Protein Degradation Therapies, Cancer, Disease

Sanofi Signs an Agreement with Google to Develop Virtual Innovation Lab for Transforming Healthcare Services

11. Sanofi Signs an Agreement with Google to Develop Virtual Innovation Lab for Transforming Healthcare Services

Published: June 18, 2019 | Tags: Sanofi, Signs, Agreement, Google, Develop, Virtual, Innovation Lab, Transforming, Healthcare, Services

Bristol-Myers Squibb to Sell its Manufacturing Facility to Catalent in Anagni, Italy

12. Bristol-Myers Squibb to Sell its Manufacturing Facility to Catalent in Anagni, Italy

Published: June 19, 2019 | Tags: Catalent, Buy, Manufacturing Facility, Bristol-Myers Squibb, Anagni, Italy

Roche’s Hemlibra (emicizumab injection) Receives Health Canada Approval for Patients with Hemophilia A Without Factor VIII Inhibitors

13. Roche’s Hemlibra (emicizumab injection) Receives Health Canada Approval for Patients with Hemophilia A Without Factor VIII Inhibitors

Published: June 18, 2019 | Tags: Roche, Hemlibra, emicizumab injection, Receives, Health Canada, Approval, Patients, Hemophilia A Without Factor VIII Inhibitors

AstraZeneca’s Breztri Aerosphere (PT010) and Bevespi Aerosphere Receive MHLW’s Approval for Chronic Obstructive Pulmonary Disease

14.AstraZeneca’s Breztri Aerosphere (PT010) and Bevespi Aerosphere Receive MHLW’s Approval for Chronic Obstructive Pulmonary Disease in Japan

Published: June 19, 2019 | Tags: AstraZeneca, Breztri Aerosphere, PT010, Bevespi Aerosphere, Receive, MHLW, Approval, Chronic Obstructive Pulmonary Disease

Ironwood and Allergan Report Positive Results of Inzess (linaclotide) in P-IIIb Trial for Patients with Irritable Bowel Syndrome with Constipation

15. Ironwood and Allergan Report Positive Results of Inzess (linaclotide) in P-IIIb Trial for Patients with Irritable Bowel Syndrome with Constipation

Published: June 19, 2019 | Tags: Ironwood, Allergan, Report, Positive, Results, Inzess, linaclotide, P-IIIb, Trial, Patients, Irritable Bowel Syndrome with Constipation, IBS-C           

Merck’s Keytruda (pembrolizumab) Receives FDA’s Accelerated Approval as a Monotherapy for Metastatic Small Cell Lung Cancer

16. Merck’s Keytruda (pembrolizumab) Receives FDA’s Accelerated Approval as a Monotherapy for Metastatic Small Cell Lung Cancer

Published: June 19, 2019 | Tags: Merck, Keytruda, pembrolizumab, Receives, FDA, Approval, Monotherapy, Metastatic, Small Cell Lung Cancer

Abbott Launches Afinion HbA1c Dx (Rapid Point-Of-Care Test) to Aid the Diagnosis of Diabetes

17. Abbott Launches Afinion HbA1c Dx (Rapid Point-Of-Care Test) to Aid the Diagnosis of Diabetes

Published: June 17, 2019 | Tags: Abbott, Launches, Afinion HbA1c Dx, Rapid Point-Of-Care, Test, Aid, Diagnosis, Diabetes

AstraZeneca and MSD’s Lynparza (olaparib) Receive European Commission’s Approval as 1L Maintenance Treatment for BRCA-Mutated Advanced Ovarian Cancer

18. AstraZeneca and MSD’s Lynparza (olaparib) Receive European Commission’s Approval as 1L Maintenance Treatment for BRCA-Mutated Advanced Ovarian Cancer

Published: June 18, 2019 | Tags: AstraZeneca, MSD, Lynparza, olaparib, Receive, European Commission, Approval, 1L, Maintenance Treatment, BRCA-Mutated, Advanced, Ovarian Cancer

Roche’s Rozlytrek (entrectinib) Receives MHLW’s Approval for NTRK Fusion-Positive Advanced Recurrent Solid Tumors in Adult and Pediatric Patients in Japan

19. Roche’s Rozlytrek (entrectinib) Receives MHLW’s Approval for NTRK Fusion-Positive Advanced Recurrent Solid Tumors in Adult and Pediatric Patients in Japan

Published: June 18, 2019 | Tags: Roche, Rozlytrek, entrectinib, Receives, MHLW, Approval, NTRK Fusion-Positive, Advanced, Recurrent, Solid Tumors, Adult, Pediatric, Patients

BeiGene Terminates its Worldwide Development and Commercialization Agreement with Celgene for Tislelizumab

20. BeiGene Terminates its Worldwide Development and Commercialization Agreement with Celgene for Tislelizumab

Published: June 17, 2019 | Tags: BeiGene, Terminates, Worldwide, Development, Commercialization, Agreement, Celgene, Tislelizumab

Novo Nordisk’s Victoza (liraglutide) Receives FDA’s Approval for Type 2 Diabetes in Children and Adolescents

21. Novo Nordisk’s Victoza (liraglutide) Receives FDA’s Approval for Type 2 Diabetes in Children and Adolescents

Published: June 17, 2019 | Tags: Novo Nordisk, Victoza, liraglutide, Receives, FDA, Approval, Type 2, Diabetes, Children, Adolescents

Immunophotonics Signs a Research Agreement with Clinical Laserthermia Clinical Laserthermia Systems for Cancer Patients with Solid Tumors

22.Immunophotonics Signs a Research Agreement with Clinical Laserthermia Clinical Laserthermia Systems for Cancer Patients with Solid Tumors

Published: June 14, 2019 | Tags: Immunophotonics, Signs, Research, Agreement, Clinical Laserthermia Systems, Cancer Patients, Solid Tumors

AstraZeneca Reports Results of Calquence (acalabrutinib) in P-III ASCEND Study for R/R Chronic Lymphocytic leukaemia #EHA2019

23. AstraZeneca Reports Results of Calquence (acalabrutinib) in P-III ASCEND Study for R/R Chronic Lymphocytic Leukemia #EHA2019

Published: June 17, 2019 | Tags: AstraZeneca, Reports, Results, Calquence, acalabrutinib, P-III, ASCEND, Study, R/R, Chronic Lymphocytic leukaemia, #EHA2019

Pfizer to Acquire Array Biopharma for ~$11.4B

24. Pfizer to Acquire Array Biopharma for ~$11.4B

Published: June 17, 2019 | Tags: Pfizer, Acquire, Array Biopharma, ~$11.4B

Janssens Reports Results of Tremfya (guselkumab) in Two P-III DISCOVER Studies for Psoriatic Arthritis

25. Janssen Reports Results of Tremfya (guselkumab) in Two P-III DISCOVER Studies for Psoriatic Arthritis

Published: June 14, 2019 | Tags: Janssens, Reports, Results, Tremfya, guselkumab, P-III, Two, DISCOVER, Studies, Psoriatic Arthritis